• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Omada Health Inc.

    8/14/25 4:17:07 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care
    Get the next $OMDA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Omada Health, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    68170A108

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68170A108


    1Names of Reporting Persons

    U.S. Venture Partners X, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,571,769.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,571,769.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,571,769.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The reported securities are owned directly by U.S. Venture Partners X, L.P. (USVP X). Presidio Management Group X, L.L.C. (PMG X) is the general partner of each of the USVP X Funds (as defined below) and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Dr. Jonathan Root, a member of the Issuer's board of directors, Irwin Federman, Steven Krausz and Richard Lewis are the managing members of PMG X, who may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. In addition, Casey M. Tansey is the managing partner of PMG X and may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein. The amount beneficially owned by each Reporting Person is determined based on 57,574,921 shares of Common Stock outstanding as of August 5, 2025 as reported by the Issuer in its Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the Commission) on August 8, 2025 (the Form 10-Q).


    SCHEDULE 13G

    CUSIP No.
    68170A108


    1Names of Reporting Persons

    USVP X Affiliates, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    146,257.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    146,257.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    146,257.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Consists of (i) 4,571,769 shares of Common Stock held directly by USVP X, and (ii) 146,257 shares of Common Stock held directly by USVP X Affiliates. PMG X is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Dr. Jonathan Root, a member of the Issuer's board of directors, Irwin Federman, Steven Krausz and Richard Lewis are the managing members of PMG X, who may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. In addition, Casey M. Tansey is the managing partner of PMG X and may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein. The amount beneficially owned by each Reporting Person is determined based on 57,574,921 shares of Common Stock outstanding as of August 5, 2025 as reported by the Issuer in its Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    68170A108


    1Names of Reporting Persons

    Presidio Management Group X, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,718,026.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,718,026.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,718,026.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Consists of (i) 4,571,769 shares of Common Stock held directly by USVP X, and (ii) 146,257 shares of Common Stock held directly by USVP X Affiliates. PMG X is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Dr. Jonathan Root, a member of the Issuer's board of directors, Irwin Federman, Steven Krausz and Richard Lewis are the managing members of PMG X, who may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. In addition, Casey M. Tansey is the managing partner of PMG X and may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein. The amount beneficially owned by each Reporting Person is determined based on 57,574,921 shares of Common Stock outstanding as of August 5, 2025 as reported by the Issuer in its Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    68170A108


    1Names of Reporting Persons

    Casey M Tansey
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,718,026.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,718,026.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,718,026.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.2 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Consists of (i) 4,571,769 shares of Common Stock held directly by USVP X, and (ii) 146,257 shares of Common Stock held directly by USVP X Affiliates. PMG X is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Dr. Jonathan Root, a member of the Issuer's board of directors, Irwin Federman, Steven Krausz and Richard Lewis are the managing members of PMG X, who may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. In addition, Casey M. Tansey is the managing partner of PMG X and may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein. The amount beneficially owned by each Reporting Person is determined based on 57,574,921 shares of Common Stock outstanding as of August 5, 2025 as reported by the Issuer in its Form 10-Q.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Omada Health, Inc.
    (b)Address of issuer's principal executive offices:

    611 Gateway Blvd, Suite 120, South San Francisco, CA 94080
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed on behalf of (i) U.S. Venture Partners X, L.P., a Delaware limited partnership, (ii) USVP X Affiliates, L.P., a Delaware limited partnership, (iii) Presidio Management Group X, L.L.C., a Delaware limited liability company and (iv) Casey M. Tansey, a citizen of the United States (the foregoing entities and individuals are collectively referred to as the Reporting Persons). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    The principal business office of the Reporting Persons is 1460 El Camino Real, Suite 100, Menlo Park, California 94025.
    (c)Citizenship:

    See Item 2(a)
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    68170A108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding comments.
    (b)Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding comments.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of the cover page for each Reporting Person and the corresponding comments.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of the cover page for each Reporting Person and the corresponding comments.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of the cover page for each Reporting Person and the corresponding comments.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of the cover page for each Reporting Person and the corresponding comments.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    U.S. Venture Partners X, L.P.
     
    Signature:/s/ Dale Holladay
    Name/Title:Dale Holladay, Authorized Signatory
    Date:08/14/2025
     
    USVP X Affiliates, L.P.
     
    Signature:/s/ Dale Holladay
    Name/Title:Dale Holladay, Authorized Signatory
    Date:08/14/2025
     
    Presidio Management Group X, L.L.C.
     
    Signature:/s/ Dale Holladay
    Name/Title:Dale Holladay, Authorized Signatory
    Date:08/14/2025
     
    Casey M Tansey
     
    Signature:/s/ Dale Holladay, Attorney-in-Fact for Casey M. Tansey
    Name/Title:Dale Holladay, Attorney-in-Fact
    Date:08/14/2025
    Get the next $OMDA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMDA

    DatePrice TargetRatingAnalyst
    7/1/2025$21.00Outperform
    Evercore ISI
    7/1/2025$25.00Overweight
    Morgan Stanley
    7/1/2025$19.00Overweight
    Analyst
    7/1/2025$23.00Buy
    Needham
    7/1/2025$21.00Overweight
    Barclays
    7/1/2025$29.00Buy
    Goldman
    7/1/2025$27.00Buy
    Canaccord Genuity
    More analyst ratings

    $OMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Omada Health with a new price target

    Evercore ISI initiated coverage of Omada Health with a rating of Outperform and set a new price target of $21.00

    7/1/25 8:41:36 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Morgan Stanley initiated coverage on Omada Health with a new price target

    Morgan Stanley initiated coverage of Omada Health with a rating of Overweight and set a new price target of $25.00

    7/1/25 8:21:32 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Analyst initiated coverage on Omada Health with a new price target

    Analyst initiated coverage of Omada Health with a rating of Overweight and set a new price target of $19.00

    7/1/25 8:21:32 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hilleman Jeryl L was granted 376 shares, increasing direct ownership by 4% to 10,112 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    7/8/25 5:18:11 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Director Root Jonathan D was granted 237 shares, increasing direct ownership by 2% to 9,973 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    7/8/25 4:15:30 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Director Fetter Trevor was granted 257 shares, increasing direct ownership by 3% to 9,993 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    7/8/25 4:14:24 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $OMDA
    SEC Filings

    View All

    Omada Health Reports Second Quarter 2025 Results

    Revenue of $61 million, up 49%52% Member Growth and Significant Progress Toward Profitability SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) --  Omada Health, Inc. (NASDAQ:OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Highlights Total Members of 752,000, up 52% compared to the second quarter of 2024Revenue of $61 million, up 49% compared to the second quarter of 2024GLP-1 Companion Success, with strong growth in members being supported by Omada's GLP-1 companion programs - now available through two of the largest pharmacy benefit managers in the United StatesOmada Horizon Day: In M

    8/7/25 4:05:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

    SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l

    7/17/25 4:30:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

    SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in

    6/17/25 9:00:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    SEC Form SCHEDULE 13G filed by Omada Health Inc.

    SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)

    8/14/25 4:17:07 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    SEC Form SCHEDULE 13G filed by Omada Health Inc.

    SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)

    8/14/25 4:15:16 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by Omada Health Inc.

    10-Q - Omada Health, Inc. (0001611115) (Filer)

    8/8/25 4:16:56 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Leadership Updates

    Live Leadership Updates

    View All

    Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

    SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in

    6/17/25 9:00:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Financials

    Live finance-specific insights

    View All

    Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

    SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l

    7/17/25 4:30:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care